AstraZeneca (NYSE:AZN) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Thursday.

Several other equities research analysts have also commented on the stock. Jefferies Financial Group lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Zacks Investment Research raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, July 16th. Finally, Morningstar reaffirmed a “hold” rating on shares of AstraZeneca in a research report on Tuesday, June 12th. Five equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $38.94.

Shares of NYSE AZN traded up $0.64 during midday trading on Thursday, hitting $39.72. 5,442,300 shares of the company’s stock traded hands, compared to its average volume of 3,968,966. AstraZeneca has a 1 year low of $31.99 and a 1 year high of $39.76. The firm has a market capitalization of $98.00 billion, a P/E ratio of 9.28, a PEG ratio of 2.05 and a beta of 0.60. The company has a quick ratio of 0.54, a current ratio of 0.72 and a debt-to-equity ratio of 1.08.

AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Thursday, July 26th. The company reported $0.69 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.38. AstraZeneca had a net margin of 11.98% and a return on equity of 29.89%. The firm had revenue of $5.16 billion during the quarter, compared to analyst estimates of $5.09 billion. During the same quarter in the prior year, the firm earned $0.87 EPS. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. equities research analysts anticipate that AstraZeneca will post 1.68 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. Bessemer Group Inc. increased its holdings in AstraZeneca by 64.3% in the 2nd quarter. Bessemer Group Inc. now owns 4,651 shares of the company’s stock worth $163,000 after acquiring an additional 1,820 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in AstraZeneca in the 2nd quarter worth approximately $175,000. Tiverton Asset Management LLC purchased a new stake in AstraZeneca in the 2nd quarter worth approximately $178,000. Gilman Hill Asset Management LLC purchased a new stake in AstraZeneca in the 2nd quarter worth approximately $205,000. Finally, Independent Advisor Alliance purchased a new stake in AstraZeneca in the 2nd quarter worth approximately $206,000. 15.97% of the stock is owned by institutional investors.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: Diversification For Individual Investors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.